IMCD N.V. (IMDZF)
| Previous Close | 151.44 |
| Open | 151.44 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 151.44 - 151.44 |
| 52 Week Range | 114.72 - 180.77 |
| Volume | |
| Avg. Volume | 7 |
| Market Cap | 8.641B |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | 27.53 |
| EPS (TTM) | 5.50 |
| Earnings Date | Aug 02, 2024 |
| Forward Dividend & Yield | 2.42 (1.60%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | N/A |
Simply Wall St.IMCD's (AMS:IMCD) five-year total shareholder returns outpace the underlying earnings growth
IMCD N.V. ( AMS:IMCD ) shareholders have seen the share price descend 13% over the month. But that doesn't change the...
GlobeNewswireIMCD reports EBITA of EUR 127 million in the first three months of 2024
IMCD_logo Logo IMCD Rotterdam, The Netherlands (26 April 2024) - IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first three months 2024 results. HIGHLIGHTS Gross profit of EUR 295 million (on a constant currency basis, equal to the first three months of 2023)Operating EBITA decline of 15% to EUR 127 million (-13% on a constant currency basis)Free cash flow of EUR 106 million (first three months o
GlobeNewswireIMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma
Photo_IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma Photographed from left to right:•Cristina Marti, Director API Sales and Strategy, IMCD Group•Gianluca Galimberti, General Manager, Cobapharma•Tess Hendriks, Legal Counsel M&A, IMCD Group•Fenna van Zanten, Director M&A, IMCD Group•Jose Alcover, Managing Director, IMCD Iberia & Maghreb ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and
